One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Senseonics Holdings, Inc.
SENS · NMS · Healthcare · Medical Devices
Current price
$8.33
52-week range
$4.79 - $10.64
Market cap
$440.44M
Balance sheet
Healthy
-13.80x Concerning
Net cash $79.84M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
1 Risk
1 rewards · 1 risks
- Reward Revenue grew 37.7% last year.
- Risk Return on equity was -118.2% last year — the company lost money on shareholders' equity.
What this company does
Senseonics Holdings, Inc.
Senseonics Holdings, Inc. sells implantable continuous glucose monitoring systems called Eversense for people with diabetes. These systems use a small sensor under the skin to track glucose levels in real-time, which is important for managing the condition. The company primarily makes money from selling these devices and the associated transmitters and apps.
How the company got here
Senseonics Holdings, Inc. was founded in 1996 and is a medical technology company focused on developing and manufacturing continuous glucose monitoring (CGM) systems for people with diabetes. [2, 3, 5, 6, 7, 9, 10, 12, 13, 14, 16] The company's journey has involved developing implantable CGM systems designed to provide long-term glucose monitoring. [9, 13, 14, 16] A significant part of their recent history includes transitioning to a fully integrated seller of their Eversense system, bringing sales, customer service, and marketing in-house. [11] This transition aimed to eliminate revenue sharing and improve responsiveness to customer needs. [11] The company has also focused on strategic partnerships and product integrations, such as with automated insulin delivery systems, to enhance the utility of their CGM technology. [11, 17]
What it actually does
Senseonics Holdings, Inc. creates implantable continuous glucose monitoring (CGM) systems for individuals with diabetes. [2, 3, 5, 6, 7, 9, 13, 14, 16] These systems help people manage their diabetes by continuously measuring glucose levels. [2, 3, 5, 6, 7, 9, 13, 14, 16] The core components include an under-the-skin sensor, a removable and rechargeable transmitter that sends data, and a mobile app that displays real-time glucose readings and alerts. [2, 3, 5, 6, 7, 9, 14] This technology allows for more informed diabetes management by providing constant insights into glucose fluctuations. [2, 3, 5, 6, 7, 9, 13, 14, 16]
Glucose Monitoring Products
Senseonics's primary business revolves around its "Glucose Monitoring Products," which are implantable continuous glucose monitoring (CGM) systems. [2, 3, 5, 6, 7, 8, 9, 13, 14, 16] This segment is the company's main revenue driver, accounting for almost all of its sales. [8] The Eversense system, including variants like Eversense XL, Eversense E3, and Eversense 365, is designed for long-term use, offering continuous measurement of glucose levels through an implanted sensor. [2, 3, 5, 6, 7, 9, 13, 16] These products are sold to healthcare providers and directly to patients, with the United States being the largest market. [8] The company has been working to bring these operations in-house to control the entire process from development to sales. [11]
What management is betting on now
Management is focused on expanding the reach and adoption of their Eversense CGM systems. [11] A key strategy involves increasing patient and prescriber awareness through targeted marketing, including social media ads and website optimization. [16] They are also emphasizing the integration of their technology with automated insulin delivery systems, like the twiist system, to offer a more comprehensive diabetes management solution. [11, 17] Furthermore, Senseonics is investing in a direct-to-consumer marketing strategy, aiming to double their patient base in the coming year. [11] The company is also exploring strategic partnerships to enhance its market position and ensure its technology remains relevant in the evolving diabetes tech landscape. [17]
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-15.02M
FY2024 Q4
$-14.28M
FY2025 Q1
$-16.51M
FY2025 Q2
$-9.39M
FY2025 Q3
$-15.98M
FY2025 Q4
$-18.36M
FY2026 Q1
$-32.14M
FY2026 Q2
$-30.36M
Revenue
$14.48M
Net income
$-36.70M
Diluted EPS
-0.63
Operating cash flow
$-30.14M
Free cash flow
$-30.36M
Fetching…
Sources
Revenue
$11.71M
Net income
$-32.33M
Diluted EPS
-0.71
Operating cash flow
$-32.02M
Free cash flow
$-32.14M
Fetching…
Sources
Revenue
$14.26M
Net income
$-69.10M
Diluted EPS
-1.19
Operating cash flow
$-17.96M
Free cash flow
$-18.36M
Fetching…
Sources
Revenue
$8.10M
Net income
$-19.53M
Diluted EPS
-0.43
Operating cash flow
$-15.82M
Free cash flow
$-15.98M
Fetching…
Sources
Revenue
$6.65M
Net income
$-14.50M
Diluted EPS
-0.02
Operating cash flow
$-9.27M
Free cash flow
$-9.39M
Fetching…
Sources
Revenue
$6.26M
Net income
$-14.26M
Diluted EPS
-0.02
Operating cash flow
$-16.08M
Free cash flow
$-16.51M
Fetching…
Sources
Revenue
$8.30M
Net income
$-78.60M
Diluted EPS
-0.02
Operating cash flow
$-14.25M
Free cash flow
$-14.28M
Fetching…
Sources
Revenue
$4.26M
Net income
$-23.98M
Diluted EPS
-0.04
Operating cash flow
$-14.81M
Free cash flow
$-15.02M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $8.33
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $79.8M - more cash than debt. Interest coverage -13.8x.
Net debt
$-79.84M
Interest coverage
-13.80x
Senseonics Holdings, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 1 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
SENS
BASELINE
Senseonics Holdings, Inc.
Total debt $62.82M Interest coverage -13.80x This is the baseline the peer rows are being compared against.
Total debt $1.40B Interest coverage 49.83x This peer still has a real interest-payment cushion, while SENS does not.
Total debt $32.72B Interest coverage 16.33x This peer still has a real interest-payment cushion, while SENS does not.
Total debt $28.15B Interest coverage 9.55x This peer still has a real interest-payment cushion, while SENS does not.
Total debt $948.40M Interest coverage 7.98x This peer still has a real interest-payment cushion, while SENS does not.
Total debt $739.25M Interest coverage -27.67x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SENS
1 Reward
1 Risk
Rewards
-
Revenue grew 37.7% last year.
Risks
-
Return on equity was -118.2% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-4.26x
P/B
4.88x
P/S
9.07x
EV/EBITDA
-3.39x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
54.9%
Operating margin
-248.5%
Net margin
-225.3%
ROE
-118.2%
ROA
-41.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.70x
Current ratio
6.75x
Quick ratio
6.22x
Total debt
$62.82M
Total cash
$142.66M
Growth
How the business has been compounding
Revenue TTM
$48.55M
Revenue 5Y CAGR
26.7%
EPS TTM
-2.23
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-95.94M
Free CF TTM
$-60.24M
FCF margin
-124.1%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—